FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896893172> ?p ?o ?g. }

• W2896893172 endingPage "e245" @default.
• W2896893172 startingPage "e244" @default.
• W2896893172 abstract "Tumor treating fields (TTFields) is a device-delivered treatment for glioblastoma (GBM) brain tumors. Post-hoc analysis of the EF-14 Trial demonstrated that the subgroup of patients age 65 or older obtained the greatest survival beneft from TTFields compared to temozolomide (TMZ) alone (HR = 0.51). The final analysis of the EF-14 Trial reported that for the subgroup of patients older than age 65, 5-year overall survival was 15% for patients treated with TTFields and maintenance TMZ, compared to no survivors in the TMZ alone arm. The objective of this analysis was to estimate the mean lifetime survival benefit of TTFields treatment for patients age 65 or older with newly diagnosed GBM. We constructed an integrated survival model that incorporated subgroup data for patients age 65 or older from the EF-14 Trial with epidemiological data on long-term GBM survival. We perfomed a literature search in the Medline database to identify epidemiological data to estimate survival in this age subgroup after the 5-year trial period. A discount rate of 3% was applied to future survival benefits. We also perfomed one-way and probabilistic sensitivity analyses and compared the results of our integrated survival model to regression based extrapolations of the trial data. Patients in this subgroup treated with TTFields and TMZ achieved an undiscounted mean lifetime survival of 3.8 years compared to 1.3 years for patients treated with TMZ alone. The resulting increase in mean lifetime survival after applying the discount rate to future health benefits was 1.8 years. Survival was 10% at 10-years and 8% at 15-years for patients treated with TTFields and TMZ. The results were most sensitive to uncertainty in long-term conditional survival estimates. This analysis of the subgroup of patients age 65 and older in the EF-14 trial demonstrated that treatment with TTFields and maintenance TMZ produced a notable increase in mean lifetime survival compared to treatment with TMZ alone. The lifetime survival benefit was achieved despite the relatively advanced age of the subgroup, reflecting the substantial survival benefit observed in the trial. The results of this analysis can inform future evaluations of the cost-effectiveness of TTFields for older patients with newly diagnosed GBM." @default.
• W2896893172 created "2018-10-26" @default.
• W2896893172 creator A5073413027 @default.
• W2896893172 creator A5080155249 @default.
• W2896893172 creator A5085357003 @default.
• W2896893172 date "2018-11-01" @default.
• W2896893172 modified "2023-09-25" @default.
• W2896893172 title "Estimated Increase in Mean Lifetime Survival for Glioblastoma Patients Age 65 Years and Older Treated with Tumor Treating Fields and Temozolomide Compared to Patients Treated with Temozolomide Alone" @default.
• W2896893172 doi "https://doi.org/10.1016/j.ijrobp.2018.07.815" @default.
• W2896893172 hasPublicationYear "2018" @default.
• W2896893172 type Work @default.
• W2896893172 sameAs 2896893172 @default.
• W2896893172 citedByCount "0" @default.
• W2896893172 crossrefType "journal-article" @default.
• W2896893172 hasAuthorship W2896893172A5073413027 @default.
• W2896893172 hasAuthorship W2896893172A5080155249 @default.
• W2896893172 hasAuthorship W2896893172A5085357003 @default.
• W2896893172 hasBestOaLocation W28968931721 @default.
• W2896893172 hasConcept C10515644 @default.
• W2896893172 hasConcept C107130276 @default.
• W2896893172 hasConcept C126322002 @default.
• W2896893172 hasConcept C143998085 @default.
• W2896893172 hasConcept C187960798 @default.
• W2896893172 hasConcept C2776194525 @default.
• W2896893172 hasConcept C2776283816 @default.
• W2896893172 hasConcept C2777389519 @default.
• W2896893172 hasConcept C502942594 @default.
• W2896893172 hasConcept C50382708 @default.
• W2896893172 hasConcept C509974204 @default.
• W2896893172 hasConcept C535046627 @default.
• W2896893172 hasConcept C67761136 @default.
• W2896893172 hasConcept C71924100 @default.
• W2896893172 hasConcept C95190672 @default.
• W2896893172 hasConceptScore W2896893172C10515644 @default.
• W2896893172 hasConceptScore W2896893172C107130276 @default.
• W2896893172 hasConceptScore W2896893172C126322002 @default.
• W2896893172 hasConceptScore W2896893172C143998085 @default.
• W2896893172 hasConceptScore W2896893172C187960798 @default.
• W2896893172 hasConceptScore W2896893172C2776194525 @default.
• W2896893172 hasConceptScore W2896893172C2776283816 @default.
• W2896893172 hasConceptScore W2896893172C2777389519 @default.
• W2896893172 hasConceptScore W2896893172C502942594 @default.
• W2896893172 hasConceptScore W2896893172C50382708 @default.
• W2896893172 hasConceptScore W2896893172C509974204 @default.
• W2896893172 hasConceptScore W2896893172C535046627 @default.
• W2896893172 hasConceptScore W2896893172C67761136 @default.
• W2896893172 hasConceptScore W2896893172C71924100 @default.
• W2896893172 hasConceptScore W2896893172C95190672 @default.
• W2896893172 hasIssue "3" @default.
• W2896893172 hasLocation W28968931721 @default.
• W2896893172 hasOpenAccess W2896893172 @default.
• W2896893172 hasPrimaryLocation W28968931721 @default.
• W2896893172 hasRelatedWork W1600263780 @default.
• W2896893172 hasRelatedWork W2370557389 @default.
• W2896893172 hasRelatedWork W2584786700 @default.
• W2896893172 hasRelatedWork W2627234075 @default.
• W2896893172 hasRelatedWork W2740613255 @default.
• W2896893172 hasRelatedWork W2760851598 @default.
• W2896893172 hasRelatedWork W2946514268 @default.
• W2896893172 hasRelatedWork W3189109524 @default.
• W2896893172 hasRelatedWork W4292454790 @default.
• W2896893172 hasRelatedWork W4295758394 @default.
• W2896893172 hasVolume "102" @default.
• W2896893172 isParatext "false" @default.
• W2896893172 isRetracted "false" @default.
• W2896893172 magId "2896893172" @default.
• W2896893172 workType "article" @default.